<code id='711756B875'></code><style id='711756B875'></style>
    • <acronym id='711756B875'></acronym>
      <center id='711756B875'><center id='711756B875'><tfoot id='711756B875'></tfoot></center><abbr id='711756B875'><dir id='711756B875'><tfoot id='711756B875'></tfoot><noframes id='711756B875'>

    • <optgroup id='711756B875'><strike id='711756B875'><sup id='711756B875'></sup></strike><code id='711756B875'></code></optgroup>
        1. <b id='711756B875'><label id='711756B875'><select id='711756B875'><dt id='711756B875'><span id='711756B875'></span></dt></select></label></b><u id='711756B875'></u>
          <i id='711756B875'><strike id='711756B875'><tt id='711756B875'><pre id='711756B875'></pre></tt></strike></i>

          Home / knowledge / explore

          explore


          explore

          author:knowledge    Page View:9
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In